When we compared GRAMD1B expression at the same distance from blood vessels across NAWM, active MS lesions, inactive MS lesions and healthy conditions, we found in the 0–100 μm group a lower expression in active lesions compared to the other conditions, and in the 100–200, 200–300 and 300–400 μm groups a higher expression in inactive MS lesions compared to the other tissues (p < 0.05). This evidence concerns the gene GRAMD1B and myeloid sarcoma.